based in israel AION Laban AI-powered drug discovery partnership between global pharmaceutical and technology companies, announces the launch of CombineAble.AI, a new startup that accelerates therapeutic development by addressing challenges associated with antibody design. Did.
CombinAble.AI was founded following AION Labs' startup challenge aimed at developing AI-based solutions for antibody therapeutics. The company plans to develop a platform that integrates computational methods and AI for biomolecular simulations for the purpose of developing new biotherapeutics.
This process includes leveraging publicly available data as well as data provided by AION Labs' pharmaceutical partners.
“Our focus is to combine a variety of advanced machine learning models, such as large-scale protein language models, molecular dynamics simulations, and multi-objective optimization algorithms, and combine them into a single system for targeted antibody discovery. AION Labs' resources and expertise provide the material and logistical support to help shape our company, refine our scientific strategy, and expand our team. As we move forward, the knowledge and insights provided by our pharmaceutical partners will be invaluable to the development and commercialization of our solutions.“ Dr. Daria Kokh, Co-Founder and CEO of CombinAble.AI said in a press release.
bigger trends
CombinAble.AI is the Venture Studio's latest startup and joins a portfolio that includes companies such as: Denova AIan AI-powered platform that discovers potential antibodies from scratch and suggests which antibodies can be used as effective drugs.
Another AION portfolio company is Promise Bio. Promise Bio is Epiproteomic analysis for precision medicine related to complex chronic diseases, including autoimmune diseases.
ten ace We leverage AI and integrate biology and machine learning algorithms to discover molecular adhesion therapies that enhance the degradation of targeted proteins. Omek AI Build a computational platform using AI. This helps researchers assess the clinical trial readiness of drug candidates, identify hidden safety liabilities, and suggest experiments to fill identified gaps.
All five companies aim to research and develop treatments.